Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing: Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies

Abstract:
NanoBio Corporation, a clinical-stage biopharmaceutical company, today announced that it has changed its corporate name to BlueWillow Biologics® in conjunction with the closing of a $10 million Series A financing. The company's new name reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines for several respiratory and sexually transmitted diseases. The Series A financing round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.

NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing: Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies

Ann Arbor, MI | Posted on May 9th, 2018

The company was originally founded as NanoBio Corporation to develop topical nanoscale therapies for various dermatology applications. BlueWillow will continue to develop skin and wound treatments through partnerships and external collaborations under the NanoBio® trademark.

BlueWillow's innovative intranasal vaccine platform is built upon the company's patented NanoVax® technology that employs a unique oil-in-water nanoemulsion adjuvant to elicit both systemic and mucosal immunity. Most infectious pathogens enter the body across mucosal surfaces, yet most vaccines today are injected and fail to elicit mucosal immunity. BlueWillow's technology has the potential to improve upon many existing vaccines as well as enable the creation of new vaccines for diseases that currently cannot be prevented through vaccination.

"Over the past several years, our research has increasingly demonstrated that our intranasal platform can play a pivotal role in the vaccines of tomorrow," said Dave Peralta, Chief Executive Officer of BlueWillow. "Much of our data points to increased protection against some of the world's most severe respiratory and sexually transmitted infections. With the commitment of our Series A investors and the tremendous support we continue to receive from the National Institutes of Health (NIH), BlueWillow is now rapidly approaching Phase 1 human clinical studies in several programs."

The name BlueWillow Biologics is a nod to the company's roots as well as a commitment to the company's future as a developer of the next generation of vaccines. "Blue" is a subtle reference to the University of Michigan, where the company's nanotechnology was discovered. While "Willow" refers to willow trees, which are known to have deep, strong roots and large, protective branches.

"The NIH, Bill & Melinda Gates Foundation, State of Michigan, Michigan Nanotechnology Institute for Medicine and Biological Sciences and the University of Michigan Technology Transfer Office have been instrumental in the advancement of BlueWillow's intranasal vaccine platform," Peralta said. "We are very grateful to each of these partners, as well as our core investors, for their support, guidance and investment in BlueWillow's promising future."

####

About BlueWillow Biologics
BlueWillow Biologics® is a privately-held biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing and commercializing intranasal vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally.

BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia. Visit BlueWillow.com for details on the company's vaccine pipeline and studies completed to date.

For more information, please click here

Copyright © BlueWillow Biologics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Epoxy compound gets a graphene bump: Rice scientists combine graphene foam, epoxy into tough, conductive composite November 14th, 2018

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

Openings/New facilities/Groundbreaking/Expansion

Rice U. announces $82 million in strategic research initiatives: Faculty, programs will expand in neuroengineering, synthetic biology, physical biology October 16th, 2018

Iranian Firm Offering Nano-Products on Chinese Market October 16th, 2018

Aculon Expands NanoProof® Product Line for Electronics Waterproofing Technology: With growing market opportunities Aculon Launches NanoProof® 8 with Push Through Connectivity™ and NanoProof® DAB a syringe application May 30th, 2017

GLOBALFOUNDRIES and Chengdu Partner to Expand FD-SOI Ecosystem in China: More than $100M investment to establish a center of excellence for FDXTM FD-SOI design May 23rd, 2017

Nanomedicine

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

WSU researchers develop new technique to understand biology at the nanoscale November 7th, 2018

A record-long polymer DNA negative November 6th, 2018

Announcements

Epoxy compound gets a graphene bump: Rice scientists combine graphene foam, epoxy into tough, conductive composite November 14th, 2018

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

Nanobiotechnology

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

WSU researchers develop new technique to understand biology at the nanoscale November 7th, 2018

A record-long polymer DNA negative November 6th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project